Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
![Vertex Pharmaceuticals logo](/files/LOGO/875320-VRTX.png)
Company profile
Ticker
VRTX
Exchange
Website
CEO
Reshma Kewalramani
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Vertex Pharmaceuticals (San Diego) LLC • Vertex Pharmaceuticals (Distribution) Incorporated • Vertex Pharmaceuticals (Cayman) Limited • Vertex Pharmaceuticals (Cayman III) Limited • Vertex Pharmaceuticals (Cayman 509) Limited • Vertex Pharmaceuticals (Cayman 765) Limited • Vertex Pharmaceuticals (Cayman 787) Limited • Vertex Pharmaceuticals (Delaware) LLC • Vertex Pharmaceuticals (Puerto Rico) LLC • Vertex Pharmaceuticals (Canada) Incorporated ...
IRS number
43039129
VRTX stock data
Latest filings (excl ownership)
8-K
Other Events
27 Jun 24
8-K
Other Events
20 May 24
SC TO-T/A
Third party tender offer statement (amended)
20 May 24
8-K
Submission of Matters to a Vote of Security Holders
15 May 24
SC TO-T/A
Third party tender offer statement (amended)
10 May 24
SC TO-T/A
Third party tender offer statement (amended)
8 May 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Vertex Reports First Quarter 2024 Financial Results
6 May 24
SC TO-T
Third party tender offer statement
22 Apr 24
PX14A6G
Letter to shareholders
16 Apr 24
Transcripts
VRTX
Earnings call transcript
2024 Q1
6 May 24
VRTX
Earnings call transcript
2023 Q4
5 Feb 24
VRTX
Earnings call transcript
2023 Q3
6 Nov 23
VRTX
Earnings call transcript
2023 Q2
1 Aug 23
VRTX
Earnings call transcript
2023 Q2
1 Aug 23
VRTX
Earnings call transcript
2023 Q1
1 May 23
VRTX
Earnings call transcript
2022 Q4
7 Feb 23
VRTX
Earnings call transcript
2022 Q3
28 Oct 22
VRTX
Earnings call transcript
2022 Q2
5 Aug 22
VRTX
Earnings call transcript
2022 Q1
6 May 22
Latest ownership filings
4
Carmen Bozic
25 Jul 24
4
Reshma Kewalramani
24 Jul 24
144
Notice of proposed sale of securities
24 Jul 24
144
Notice of proposed sale of securities
22 Jul 24
4
BRUCE I SACHS
17 Jul 24
4
Carmen Bozic
12 Jul 24
144
Notice of proposed sale of securities
10 Jul 24
4
Carmen Bozic
28 Jun 24
144
Notice of proposed sale of securities
26 Jun 24
4
Carmen Bozic
13 Jun 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.17 bn | 9.17 bn | 9.17 bn | 9.17 bn | 9.17 bn | 9.17 bn |
Cash burn (monthly) | 400.97 mm | 10.52 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 1.55 bn | 40.67 mm | n/a | n/a | n/a | n/a |
Cash remaining | 7.62 bn | 9.13 bn | n/a | n/a | n/a | n/a |
Runway (months of cash) | 19.0 | 868.0 | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2024
88.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1405 |
Opened positions | 365 |
Closed positions | 135 |
Increased positions | 486 |
Reduced positions | 394 |
13F shares | Current |
---|---|
Total value | 88.02 tn |
Total shares | 228.73 mm |
Total puts | 1.48 mm |
Total calls | 1.35 mm |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Capital World Investors | 25.57 mm | $10.69 tn |
Vanguard | 22.68 mm | $9.48 tn |
BLK Blackrock | 21.96 mm | $9.18 tn |
STT State Street | 12.01 mm | $5.02 tn |
FMR | 10.67 mm | $4.46 tn |
Alliancebernstein | 7.10 mm | $2.97 tn |
JPM JPMorgan Chase & Co. | 6.02 mm | $2.52 tn |
Geode Capital Management | 5.81 mm | $2.42 tn |
Capital Research Global Investors | 5.74 mm | $2.40 tn |
Jennison Associates | 4.78 mm | $2.00 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Jul 24 | Bozic Carmen | Common Stock | Sell | Dispose S | No | Yes | 488.46 | 2,280 | 1.11 mm | 25,539 |
22 Jul 24 | Kewalramani Reshma | Common Stock | Sell | Dispose S | No | Yes | 497 | 15,202 | 7.56 mm | 106,172 |
15 Jul 24 | Sachs Bruce I | Deferred Stock Units Common Stock | Grant | Acquire A | No | No | 490.12 | 89.264 | 43.75 k | 14,943.012 |
10 Jul 24 | Bozic Carmen | Common Stock | Sell | Dispose S | No | Yes | 487.34 | 2,280 | 1.11 mm | 27,819 |
26 Jun 24 | Bozic Carmen | Common Stock | Sell | Dispose S | No | Yes | 471.72 | 2,280 | 1.08 mm | 30,099 |
News
Needham Reiterates Hold on Vertex Pharmaceuticals
26 Jul 24
TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $500
23 Jul 24
Here's How Much $100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today
23 Jul 24
Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $480
22 Jul 24
HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $500
19 Jul 24
Press releases
Citius Pharmaceuticals (CTXR) Eyes Breakthrough with Late-Stage Drug Pipeline Poised for Regulatory Approval
17 Jul 24
Genomics plc Announces New Extension and Expansion of Drug Discovery Collaboration with Vertex
16 Jul 24
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations
15 Jul 24
Citius Pharmaceuticals (CTXR) Nears Key FDA Decisions and Launch Plans for 2024
11 Jul 24
FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment
9 Jul 24